Clinical trial NCT03346304: Photodynamic Therapy for the Prevention of Lung Cancer
Official title: Photodynamic Therapy for the Prevention of Lung Cancer (PEARL)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Squamous Cell Lung Cancer
Lung Cancer
Keywords: Autofluorescence Broncoscopy (AFB)
Photodynamic Therapy (PDT)
High Grade Lesions (HGLs)
lung cancer
photosensitiser
Fotolon
Lead sponsor: University College, London
Sponsor class: OTHER
First posted: 2017-11-17
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: PEARL is a phase III multicentre 2:1 randomised controlled trial, with an incorporated phase II (pilot) component. All patients consented/registered onto the trial will have an autofluorescence bronchoscopy (AFB) to check for the presence of high grade lesions (HGLs) in the lung, as verified by tissue biopsy. Only patients with one or more histologically confirmed lung HGL will be randomised to receive either photodynamic therapy (PDT) treatment with surveillance (=intervention), or surveillance alone (=control).

The overall aim of the phase II pilot is to demonstrate a \>20% response in the PDT group (at least 3 out of 21 PDT patients), compared to a minimum response of 5%. This will be used as an efficacy signal to determine whether the trial will continue into phase III. Response will be measured by regression of high grade lesions (HGLs) to either low grade lesions (LGLs), or to normal epithelium at 6 months post treatment (blind assessment). The overall aim of the phase III is to show that the time period over which HGLs progress to invasive lung cancer is significantly longer when treated with PDT compared to surveillance alone.

Detailed description: Background: Squamous cell carcinoma of the lung develops through a transition of progressive cytological aberration, from normal to metaplasia, mild, moderate, and severe dysplasia and then carcinoma in situ (CIS) before becoming an invasive cancer. Progression rates to invasive carcinoma can vary depending on the initial grade of lesion and it is generally accepted that high-grade lesions are more likely to progress to invasive cancer than low-grade lesions. Early detection and treatment of these lesions is critical to improving survival. There is no evidence base examining how, or whether these high-grade lesions (HGLs) should be treated, resulting in diverse treatment practices both nationally and internationally. This is the first randomised clinical trial of a bronchoscopic intervention in treating HGLs using PDT.

Treatment: Treatment-arm patients will receive two courses of PDT treatment using the photosensitiser drug Fotolon®. Fotolon®, which preferentially accumulates in HGLs, is first administered via IV infusion. Patients then undergo bronchoscopy during which their HGLs are irradiated with red light (via non-heat emitting laser). Red-light activation of the photosensitiser causes chemical transformation of the cells and cell death.

Follow Up: Follow up in both arms consists of AFB surveillance at 6 and 12 months, then every 6-12 months (depending on the appearance of lesions), with annual CT scanning of the thorax, and annual spirometry. Biological samples for translational analysis will be taken at baseline and each subsequent trial visit.

Duration of recruitment: Anticipated recruitment for phase II is 1 year (12 months), and an additional 2 years (24 months) for the phase III.

Eligibility criteria: Inclusion Criteria:

1. Patients with ≥1 histologically confirmed lung HGL (defined as severe dysplasia or carcinoma in situ) PRE-REGISTRATION: High likelihood of presence of lung HGLs as evaluated by investigator (e.g. because patient part of existing surveillance cohort or referred to trial site) and inclusion/exclusion criteria below. PRE-RANDOMISATION: Following registration and AFB, only patients with ≥1 lung HGLs confirmed histologically can be continue to randomisation provided they continue to meet inclusion/exclusion criteria below.
2. Absence of metastatic disease or other primary cancers as confirmed by CT thorax within 28 days prior to registration only)
3. Male or female patients ≥18 years of age
4. No upper age limit but life expectancy must be at least 3 years
5. ECOG Performance Score 0-2
6. FEV1 ≥ 25% of predicted
7. DLCO/TLCO ≥ 20% of predicted (within 28 days prior to registration only)
8. Women of child-bearing potential (WOCBP), or men with female partners who are pregnant or WOCBP must be willing to practise highly effective methods of birth control starting as soon as possible from the time of informed consent and registration until randomisation (if randomised to the control arm), or until 3 months after the end of their last PDT treatment (if randomised to the intervention arm) . Male patients must also advise their female partners who are WOCBP regarding contraceptive requirements as listed for female patients who are WOCBP.
9. Patients who are WOCBP must also have a negative pregnancy test at the following time points:

   * within 14 days prior to registration
   * within 21 days prior to randomisation
   * and within 24 hours prior to 1st and 2nd PDT treatment, for each lung treated (only if randomised to PDT arm)
10. Ability to give informed consent including the donation of biological samples for translational research

Exclusion criteria:

1. PRE-RANDOMISATION: Finding of (micro)-invasive disease on histology
2. HGLs present for ≥5 years which have remained stable on autofluorescence bronchoscopy (AFB) surveillance
3. Detection of active cancer or on systemic treatment for cancer, excluding basal cell skin cancers (unless adjacent to the illumination site)
4. Previous radiotherapy to the central airways
5. ECOG Performance Score \>2
6. Patients who are anticoagulated for prosthetic heart valves
7. Decompensated heart disease with life expectancy less than 3 years
8. Severe liver and renal insufficiency with life expectancy less than 3 years
9. Porphyria or hypersensitivity against porphyrins or photosensitivity
10. Hypersensitivity to chlorine-e6-trisodium salt or therapy with another photosensitising agent or relevant antibiotics (macrolides) in the last 4 weeks
11. Ophthalmic disease likely to require slit-lamp examination within 60 days of registration/randomisation
12. Planned surgical procedure within 60 days of registration/randomisation
13. Patient unlikely to cooperate with a 3-year follow-up; medical or psychological condition at the discretion of the investigator which would not permit compliance with the protocol or meaningful signed informed consent
14. Participation in another study with an investigational medicinal product within one month prior to registration/randomisation
15. Pregnant or breast feeding women (confirmed by serum/urine ß-HCG)
16. Any other condition which is assessed as an intolerable risk by the investigator upon inclusion in the study

Primary outcomes:
measure: Time to site-specific progression
timeFrame: within a 3-year follow-up (incorporates patients from phase II)
Secondary outcomes:
measure: Site-specific response
timeFrame: within a 3-year follow-up (incorporates patients from phase II)
measure: Number of new HGLs
timeFrame: within a 3-year follow-up (incorporates patients from phase II)
measure: Number of metachronous endobronchial lung cancers
timeFrame: within a 3-year follow-up (incorporates patients from phase II)
measure: Cumulative risk of developing lung cancer
timeFrame: within a 3-year follow-up (incorporates patients from phase II)
measure: Overall and cancer specific survival
timeFrame: within a 3-year follow-up (incorporates patients from phase II)
measure: Difference in spirometry (FEV1, FVC) values
timeFrame: at specific time points (6,12,24 and 36 months post randomisation);
measure: Adverse events
timeFrame: within a 3-year follow-up (incorporates patients from phase II)
measure: EQ-5D-5L
timeFrame: at specific time points (6,12,24 and 36 months, and possibly 18 and 30 months, post randomisation); compared between the PDT and control groups
measure: EORTC QLQ-LC13
timeFrame: at specific time points (6,12,24 and 36 months, and possibly 18 and 30 months, post randomisation); compared between the PDT and control groups
measure: ACE-27
timeFrame: at specific time points (6,12,24 and 36 months, and possibly 18 and 30 months, post randomisation); compared between the PDT and control groups
Other outcomes:
Locations:
Study officials:
References: